Gilead Sciences (GILD) Raises Quarterly Dividend 10.5% to $0.63; 3.6% Yield
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
Go back to Gilead Sciences (GILD) Raises Quarterly Dividend 10.5% to $0.63; 3.6% Yield
February 5, 2019 9:00 AM EST
Raymond James analyst Steven Seedhouse lowered the price target on Gilead Sciences (NASDAQ: GILD) to $90.00 (from $92.00) while maintaining a Strong Buy rating.
...
More
February 5, 2019 6:59 AM EST
Citi analyst Robyn Karnauskas lowered the price target on Gilead Sciences (NASDAQ: GILD) to $100.00 (from $106.00) while maintaining a Buy rating. 2019 guidance anticipates double-digit y/y HIV growth and HCV stabilization. The company guided for generic impact in HCV, Letairis and Ranexa of ~$2.2B with... More
February 5, 2019 6:46 AM EST
RBC Capital analyst Brian Abrahams raised the price target on Gilead Sciences (NASDAQ: GILD) to $89.00 (from $86.00) while maintaining a Outperform rating following fourth quarter results.
Abrahams commented, "Parsing out the one-time effects that inflated HIV but depressed earnings this quarter,... More
February 4, 2019 4:02 PM EST
Gilead Sciences (NASDAQ: GILD) reported Q4 EPS of $1.44, $0.27 worse than the analyst estimate of $1.71. Revenue for the quarter came in at $5.8 billion versus the consensus estimate of $5.49 billion.
GUIDANCE:
Gilead Sciences sees FY2019 revenue of $21.3-21.8 billion, versus the consensus... More
